Teva Pharmaceutical Industries perks up on below-average volume on the heels of rumblings that it is fielding interest for its Medis business, a unit that it considered divesting more than a year ago.
Date: September 17, 2018
Source: Seeking Alpha
Coffee with DistilINFO's Morning Updates...
Sign up for DistilINFO e-Newsletters.
Related Stories
BrightStar Care Continues Nationwide Expansion with Franchise Owner’s Acquisition of Harmony Home Care
Retrophin Buys Orphan Technologies for $517 Million to Gain Enzyme Replacement Therapy
Philips, Ibex Medical Analytics Partner on AI-Powered Digital Pathology Adoption
Heal Kicks Off Telepsychology Service for California Residents
Liminal Biosciences Announces Signature of a Share Purchase Agreement for Sale of Remaining Plasma-Derived Business with Kedrion
Cantel expands life sciences portfolio with $17M acquisition of Stericycle’s CES business
Future Market Insights Analyzes Impact of COVID-19 on Heparin-Induced Thrombocytopenia (HIT) Treatment Market; Stakeholders to Focus on Long-term Dimensions
Innovaccer Unveils the Innovation Accelerator Program with 14 Digital Health Innovators